Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
Ignacio Salamanca de la CuevaElisa CinconzeTamara EckermannUgo NwojiLode GodderisEmily LuXavier Martínez-GómezHuajun WangEmad YanniPublished in: Drug safety (2021)
No serious AEs related to GSK's IIV4 within 7 days post vaccination were reported. This study supports the favourable risk-benefit safety profile of GSK's IIV4.